Record #1 of 12
ID: CD000222
AU: Cheng Katharine
AU: Ashby Deborah
AU: Smyth Rosalind L
TI: Ursodeoxycholic acid for cystic fibrosis-related liver disease
SO: Cochrane Database of Systematic Reviews
YR: 2014
NO: 12
PB: John Wiley & Sons, Ltd
KY: Bile [secretion];Cholagogues and Choleretics [therapeutic use];Chronic Disease;Cystic Fibrosis [complications];Liver [enzymology];Liver Diseases [etiology] [prevention & control];Randomized Controlled Trials as Topic;Ursodeoxycholic Acid [therapeutic use];Adolescent[checkword];Adult[checkword];Child[checkword];Child, Preschool[checkword];Humans[checkword]
CC: CF
DOI: 10.1002/14651858.CD000222.pub3
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000222.pub3/abstract


Record #2 of 12
ID: CD011602
AU: Pavlov Chavdar S
AU: Casazza Giovanni
AU: Semenistaia Marianna
AU: Nikolova Dimitrinka
AU: Tsochatzis Emmanuel
AU: Liusina Ekaterina
AU: Ivashkin Vladimir T
AU: Gluud Christian
TI: Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
SO: Cochrane Database of Systematic Reviews
YR: 2016
NO: 3
PB: John Wiley & Sons, Ltd
KY: Liver Cirrhosis, Alcoholic [diagnostic imaging];Liver Diseases, Alcoholic [complications];Prospective Studies;Ultrasonography;Female[checkword];Humans[checkword];Male[checkword]
DOI: 10.1002/14651858.CD011602.pub2
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011602.pub2/abstract


Record #3 of 12
ID: CD012056
AU: Palaniappan Senthil K
AU: Than Nan Nitra
AU: Thein Aung Win
AU: Moe Soe
AU: van Mourik Indra
TI: Interventions for preventing and managing advanced liver disease in cystic fibrosis
SO: Cochrane Database of Systematic Reviews
YR: 2017
NO: 8
PB: John Wiley & Sons, Ltd
DOI: 10.1002/14651858.CD012056.pub2
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012056.pub2/abstract


Record #4 of 12
ID: CD006573
AU: Gurusamy Kurinchi Selvan
AU: Tsochatzis Emmanuel
AU: Toon Clare D
AU: Davidson Brian R
AU: Burroughs Andrew K
TI: Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation
SO: Cochrane Database of Systematic Reviews
YR: 2013
NO: 12
PB: John Wiley & Sons, Ltd
KY: Liver Transplantation;Antiviral Agents [adverse effects] [therapeutic use];Genotype;Graft Rejection [epidemiology];Graft Survival;Hepacivirus [genetics];Hepatitis C, Chronic [drug therapy] [mortality] [prevention & control] [surgery];Interferon-alpha [adverse effects] [therapeutic use];Polyethylene Glycols [adverse effects] [therapeutic use];Recombinant Proteins;Ribavirin [adverse effects] [therapeutic use];Secondary Prevention;Humans[checkword]
CC: LIVER
DOI: 10.1002/14651858.CD006573.pub3
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006573.pub3/abstract


Record #5 of 12
ID: CD006803
AU: Gurusamy Kurinchi Selvan
AU: Tsochatzis Emmanuel
AU: Toon Clare D
AU: Xirouchakis Elias
AU: Burroughs Andrew K
AU: Davidson Brian R
TI: Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus
SO: Cochrane Database of Systematic Reviews
YR: 2013
NO: 12
PB: John Wiley & Sons, Ltd
KY: Antiviral Agents [adverse effects] [therapeutic use];Drug Therapy, Combination [adverse effects] [methods];Genotype;Graft Rejection [epidemiology];Hepacivirus [genetics];Hepatitis C [drug therapy] [mortality];Interferon-alpha [therapeutic use];Liver Cirrhosis;Liver Transplantation [adverse effects] [mortality];Polyethylene Glycols [therapeutic use];Randomized Controlled Trials as Topic;Recombinant Proteins [therapeutic use];Recurrence;Reoperation;Ribavirin [adverse effects] [therapeutic use];Humans[checkword]
CC: LIVER
DOI: 10.1002/14651858.CD006803.pub4
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006803.pub4/abstract


Record #6 of 12
ID: CD003617
AU: Koretz Ronald L
AU: Pleguezuelo Maria
AU: Arvaniti Vasiliki
AU: Barrera Baena Pilar
AU: Ciria Ruben
AU: Gurusamy Kurinchi Selvan
AU: Davidson Brian R
AU: Burroughs Andrew K
TI: Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C
SO: Cochrane Database of Systematic Reviews
YR: 2013
NO: 1
PB: John Wiley & Sons, Ltd
KY: Antiviral Agents [adverse effects] [therapeutic use];Hepatitis C, Chronic [drug therapy] [mortality] [virology];Interferon-alpha [therapeutic use];Interferons [adverse effects] [therapeutic use];Liver Cirrhosis [drug therapy] [etiology];Polyethylene Glycols [therapeutic use];Randomized Controlled Trials as Topic;Recombinant Proteins [therapeutic use];Recurrence;Viral Load;Humans[checkword]
CC: LIVER
DOI: 10.1002/14651858.CD003617.pub2
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003617.pub2/abstract


Record #7 of 12
ID: CD011648
AU: Saffioti Francesca
AU: Gurusamy Kurinchi Selvan
AU: Eusebi Leonardo Henry
AU: Tsochatzis Emmanuel
AU: Davidson Brian R
AU: Thorburn Douglas
TI: Pharmacological interventions for primary biliary cholangitis
SO: Cochrane Database of Systematic Reviews
YR: 2017
NO: 3
PB: John Wiley & Sons, Ltd
KY: Azathioprine [adverse effects] [therapeutic use];Chenodeoxycholic Acid [adverse effects] [analogs & derivatives] [therapeutic use];Cholagogues and Choleretics [adverse effects] [therapeutic use];Cholangitis [drug therapy] [immunology] [mortality];Chronic Disease;Colchicine [adverse effects] [therapeutic use];Cyclosporine [adverse effects] [therapeutic use];Immunosuppressive Agents [adverse effects] [therapeutic use];Methotrexate [adverse effects] [therapeutic use];Mitochondria [immunology];Network Meta-Analysis;Penicillamine [adverse effects] [therapeutic use];Quality of Life;Randomized Controlled Trials as Topic;Ursodeoxycholic Acid [adverse effects] [therapeutic use];Humans[checkword]
DOI: 10.1002/14651858.CD011648.pub2
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011648.pub2/abstract


Record #8 of 12
ID: CD004036
AU: Giljaca Vanja
AU: Poropat Goran
AU: Stimac Davor
AU: Gluud Christian
TI: Glucocorticosteroids for primary sclerosing cholangitis
SO: Cochrane Database of Systematic Reviews
YR: 2010
NO: 1
PB: John Wiley & Sons, Ltd
KY: Anti-Inflammatory Agents [adverse effects] [therapeutic use];Budesonide [therapeutic use];Cholangitis, Sclerosing [drug therapy];Hydrocortisone [adverse effects] [therapeutic use];Prednisone [therapeutic use];Randomized Controlled Trials as Topic;Therapeutic Irrigation [methods];Humans[checkword]
CC: LIVER
DOI: 10.1002/14651858.CD004036.pub3
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004036.pub3/abstract


Record #9 of 12
ID: CD009898
AU: Weitz Marcus
AU: Strahm Brigitte
AU: Meerpohl Joerg J
AU: Schmidt Maria
AU: Bassler Dirk
TI: Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients
SO: Cochrane Database of Systematic Reviews
YR: 2015
NO: 12
PB: John Wiley & Sons, Ltd
KY: Chronic Disease;Graft vs Host Disease [therapy];Hematopoietic Stem Cell Transplantation [adverse effects];Photopheresis [methods];Adolescent[checkword];Child[checkword];Humans[checkword]
DOI: 10.1002/14651858.CD009898.pub3
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009898.pub3/abstract


Record #10 of 12
ID: CD009759
AU: Weitz Marcus
AU: Strahm Brigitte
AU: Meerpohl Joerg J
AU: Schmidt Maria
AU: Bassler Dirk
TI: Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients
SO: Cochrane Database of Systematic Reviews
YR: 2015
NO: 12
PB: John Wiley & Sons, Ltd
KY: Graft vs Host Disease [therapy];Hematopoietic Stem Cell Transplantation [adverse effects];Photopheresis [methods];Adolescent[checkword];Child[checkword];Humans[checkword]
CC: CHILDCA
DOI: 10.1002/14651858.CD009759.pub3
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009759.pub3/abstract


Record #11 of 12
ID: CD009354
AU: Jameson Elisabeth
AU: Jones Simon
AU: Remmington Tracey
TI: Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I
SO: Cochrane Database of Systematic Reviews
YR: 2016
NO: 4
PB: John Wiley & Sons, Ltd
KY: Antibodies [blood];Enzyme Replacement Therapy [methods];Iduronidase [administration & dosage] [immunology] [therapeutic use];Mucopolysaccharidosis I [classification] [drug therapy];Randomized Controlled Trials as Topic;Rare Diseases [classification] [drug therapy];Severity of Illness Index;Adolescent[checkword];Adult[checkword];Child[checkword];Female[checkword];Humans[checkword];Male[checkword];Young Adult[checkword]
CC: CF
DOI: 10.1002/14651858.CD009354.pub4
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009354.pub4/abstract


Record #12 of 12
ID: CD008185
AU: da Silva Edina MK
AU: Strufaldi Maria Wany Louzada
AU: Andriolo Regis B
AU: Silva Laercio A
TI: Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
SO: Cochrane Database of Systematic Reviews
YR: 2016
NO: 2
PB: John Wiley & Sons, Ltd
KY: Drug Administration Schedule;Enzyme Replacement Therapy [methods];Iduronate Sulfatase [administration & dosage];Mucopolysaccharidosis II [drug therapy];Randomized Controlled Trials as Topic;Rare Diseases [drug therapy] [enzymology];Humans[checkword];Male[checkword]
CC: CF
DOI: 10.1002/14651858.CD008185.pub4
US: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008185.pub4/abstract